Summary
Definición
Anamnesis y examen
Principales factores de diagnóstico
- auditory hallucinations
- delusions
- avolition
- anhedonia
- asocial behavior
- affective blunting
- alogia
- cognitive deficits
- somatization
Otros factores de diagnóstico
- lack of insight (anosognosia)
- bizarre or disorganized behavior
- tangentiality and looseness of association (derailment)
- circumstantiality
- pressured speech
- distractible speech
- depression
- suicidality
- anxiety
- elation
- incongruent affect
- verbigeration
- perseveration
- word salad
- derealization
- nonauditory hallucinations
- déjà-vu
- stilted goal-directed behaviors
- catatonic symptoms
- "soft" neurologic deficits
Factores de riesgo
- family history of schizophrenia
- increasing paternal age
- obstetric complications
- cannabis use
- low IQ
- motor dysfunction
- psychological stress
- childhood abuse
- migrant status
Pruebas diagnósticas
Primeras pruebas diagnósticas para solicitar
- clinical diagnosis
Pruebas diagnósticas que deben considerarse
- MRI/CT head
- serum HIV enzyme-linked immunosorbent assay
- serum rapid plasma reagin (RPR) test
- CBC including absolute neutrophil count (ANC)
- drug toxicology screen
- BUN and electrolytes
- liver function tests
- thyroid-stimulating hormone
- pregnancy test
- genetic testing
Algoritmo de tratamiento
at risk of developing psychosis
acute psychotic episode
chronic symptoms
treatment-resistant schizophrenia
Colaboradores
Consejeros especializados
Xiaoduo Fan, MD, MPH, MSc
Professor of Psychiatry
Director, UMass MIND
UMass Memorial Health/UMass Chan Medical School
Worcester
MA
Divulgaciones
XF has received research support from Otsuka, Roche, Intra-Cellular Therapies, Avanir, and Janssen. XF holds a patent on "combination treatment for neuropsychiatric disorders" (USPTO patent # 11,331,319).
Agradecimientos
Dr Xiaoduo Fan would like to gratefully acknowledge Dr Adrian Preda and Dr Robert G. Bota, previous contributors to this topic.
Divulgaciones
AP and RGB declare that they have no competing interests.
Revisores por pares
David Taylor, PhD
Chief Pharmacist
South London and Maudsley NHS Foundation Trust
London
UK
Divulgaciones
DT declares that he has no competing interests.
Joel Yager, MD
Professor
Department of Psychiatry
University of New Mexico School of Medicine
Albuquerque
NM
Divulgaciones
JY declares that he has no competing interests.
Kemal Sagduyu, MD
Professor of Psychiatry
University of Missouri Kansas City
Kansas City
MO
Divulgaciones
KS declares that he has no competing interests.
Agradecimiento de los revisores por pares
Los temas de BMJ Best Practice se actualizan de forma continua de acuerdo con los desarrollos en la evidencia y en las guías. Los revisores por pares listados aquí han revisado el contenido al menos una vez durante la historia del tema.
Divulgaciones
Las afiliaciones y divulgaciones de los revisores por pares se refieren al momento de la revisión.
Referencias
Artículos principales
American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th ed., text revision (DSM-5-TR). Washington, DC: American Psychiatric Publishing; 2022.Texto completo
American Psychiatric Association. The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. Washington, DC: American Psychiatric Association; 2021.Texto completo
Hasan A, Falkai P, Wobrock T, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry. 2012 Jul;13(5):318-78. Resumen
Artículos de referencia
Una lista completa de las fuentes a las que se hace referencia en este tema está disponible para los usuarios con acceso a todo BMJ Best Practice.
Diferenciales
- Schizoaffective disorder
- Schizophreniform disorder and brief psychotic disorder
- Substance-induced psychotic disorder
Más DiferencialesGuías de práctica clínica
- Diagnostic and statistical manual of mental disorders, fifth edition (DSM-5-TR)
- Evidence-based guidelines for the pharmacological treatment of schizophrenia
Más Guías de práctica clínicaFolletos para el paciente
Schizophrenia: what is it?
Schizophrenia: questions to ask your doctor
Más Folletos para el pacienteInicie sesión o suscríbase para acceder a todo el BMJ Best Practice
El uso de este contenido está sujeto a nuestra cláusula de exención de responsabilidad